Cognitive profile, neuroimaging and fluid biomarkers in post-acute COVID-19 syndrome.

Autor: Guillén N; Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain., Pérez-Millan A; Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain.; Institut de Neurociències, Faculty of Medicine and Medical Sciences, University of Barcelona, Barcelona, Spain.; Department of Biomedicine, Faculty of Medicine, University of Barcelona, Barcelona, Spain., Falgàs N; Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain., Lledó-Ibáñez GM; Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain., Rami L; Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain., Sarto J; Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain., Botí MA; Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain., Arnaldos-Pérez C; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain.; Immunology Service, Biomedical Diagnostic Center, Hospital Clínic de Barcelona, Barcelona, Spain., Ruiz-García R; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain.; Immunology Service, Biomedical Diagnostic Center, Hospital Clínic de Barcelona, Barcelona, Spain., Naranjo L; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain.; Immunology Service, Biomedical Diagnostic Center, Hospital Clínic de Barcelona, Barcelona, Spain., Segura B; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain.; Institut de Neurociències, Faculty of Medicine and Medical Sciences, University of Barcelona, Barcelona, Spain.; Medical Psychology Unit, Department of Medicine, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain., Balasa M; Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain., Sala-Llonch R; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain.; Institut de Neurociències, Faculty of Medicine and Medical Sciences, University of Barcelona, Barcelona, Spain.; Department of Biomedicine, Faculty of Medicine, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain., Lladó A; Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain.; Institut de Neurociències, Faculty of Medicine and Medical Sciences, University of Barcelona, Barcelona, Spain., Gray SM; Sage Therapeutics, Cambridge, USA., Johannesen JK; Sage Therapeutics, Cambridge, USA., Pantoni MM; Sage Therapeutics, Cambridge, USA., Rutledge GA; Sage Therapeutics, Cambridge, USA., Sawant R; Sage Therapeutics, Cambridge, USA., Wang Y; Sage Therapeutics, Cambridge, USA., Watson LS; Sage Therapeutics, Cambridge, USA., Dalmau J; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain.; Institut de Neurociències, Faculty of Medicine and Medical Sciences, University of Barcelona, Barcelona, Spain.; Department of Neurology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.; Enfermedades Raras, Centro de Investigación Biomédica en Red, Madrid, Spain.; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Catalan Institute for Research and Advanced Studies (ICREA), Barcelona, Spain., Sanchez-Valle R; Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain. rsanchez@clinic.cat.; Fundació Recerca Clínic Barcelona-IDIBAPS, Barcelona, Spain. rsanchez@clinic.cat.; Institut de Neurociències, Faculty of Medicine and Medical Sciences, University of Barcelona, Barcelona, Spain. rsanchez@clinic.cat.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Jun 05; Vol. 14 (1), pp. 12927. Date of Electronic Publication: 2024 Jun 05.
DOI: 10.1038/s41598-024-63071-2
Abstrakt: We aimed to characterize the cognitive profile of post-acute COVID-19 syndrome (PACS) patients with cognitive complaints, exploring the influence of biological and psychological factors. Participants with confirmed SARS-CoV-2 infection and cognitive complaints ≥ 8 weeks post-acute phase were included. A comprehensive neuropsychological battery (NPS) and health questionnaires were administered at inclusion and at 1, 3 and 6 months. Blood samples were collected at each visit, MRI scan at baseline and at 6 months, and, optionally, cerebrospinal fluid. Cognitive features were analyzed in relation to clinical, neuroimaging, and biochemical markers at inclusion and follow-up. Forty-nine participants, with a mean time from symptom onset of 10.4 months, showed attention-executive function (69%) and verbal memory (39%) impairment. Apathy (64%), moderate-severe anxiety (57%), and severe fatigue (35%) were prevalent. Visual memory (8%) correlated with total gray matter (GM) and subcortical GM volume. Neuronal damage and inflammation markers were within normal limits. Over time, cognitive test scores, depression, apathy, anxiety scores, MRI indexes, and fluid biomarkers remained stable, although fewer participants (50% vs. 75.5%; p = 0.012) exhibited abnormal cognitive evaluations at follow-up. Altered attention/executive and verbal memory, common in PACS, persisted in most subjects without association with structural abnormalities, elevated cytokines, or neuronal damage markers.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: